
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is positioned for long-term financial growth through anticipated improvements in manufacturing efficiency, which could lead to gross margins reaching 60-70%. The strong efficacy and safety data demonstrated in the pivotal FELIX study, coupled with a positive opinion from the CHMP, provide a solid foundation for the approval and commercialization of its innovative T-cell therapies. While market potential may face challenges due to the high costs of CAR-T therapies, the company's advancements in product development indicate a commitment to addressing these challenges effectively.
Bears say
Autolus Therapeutics faces challenges in its financial outlook, primarily due to anticipated stagnant sales in Q3 2025 attributed to changes in CMS reimbursement policies, leading to a potential underperformance in CAR-T therapeutic production. The company's management projects overhead costs to stabilize at around 500 patients annually, resulting in limited scalability since additional patient intake only increases material and labor costs. Furthermore, the presence of known adverse events such as cytokine release syndrome, neurotoxicity, and severe cytopenias may further hinder the widespread adoption and market potential of its CAR-T therapies.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares